Last update 01 Jul 2024

SXC-2023

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
SXC 2023
Target
SLC7A11
Mechanism
SLC7A11 stimulants(Cystine/glutamate transporter stimulants)
Therapeutic Areas
Other Diseases
Active Indication
Cocaine-Related Disorders
Inactive Indication
Disruptive, Impulse Control, and Conduct DisordersTrichotillomania
Originator Organization
Promentis Pharmaceuticals, Inc.Promentis Pharmaceuticals, Inc.
Active Organization
Promentis Pharmaceuticals, Inc.Promentis Pharmaceuticals, Inc.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-

Structure

Molecular FormulaC15H19NO4S
InChIKeyWSPBIYTZXPCLCG-ZDUSSCGKSA-N
CAS Registry1695562-35-6

Related

5
Clinical Trials associated with SXC-2023
NCT06343532 / Not yet recruitingPhase 1IIT
Phase 1, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral SXC-2023
NCT03887429 / CompletedPhase 2
An Exploratory, Placebo-Controlled, Crossover Study to Examine the Safety and Activity of SXC-2023 to Improve Behavioral Dynamics in Non-Treatment Seeking Adults Undergoing Acute Nicotine Withdrawal
NCT03797521 / CompletedPhase 2
A Phase 2, Double Blind, Placebo-Controlled Study to Explore the Safety, Tolerability, and Activity of SXC-2023 in Adults With Moderate to Severe Trichotillomania (TTM) When Dosed for 6 Weeks
100 Clinical Results associated with SXC-2023
Login to view more data
100 Translational Medicine associated with SXC-2023
Login to view more data
100 Patents (Medical) associated with SXC-2023
Login to view more data
100 Deals associated with SXC-2023
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Disruptive, Impulse Control, and Conduct DisordersPhase 2
US
Promentis Pharmaceuticals, Inc.Promentis Pharmaceuticals, Inc.
04 Mar 2019
TrichotillomaniaPhase 2
US
Promentis Pharmaceuticals, Inc.Promentis Pharmaceuticals, Inc.
19 Dec 2018
Cocaine-Related DisordersPhase 1
US
Promentis Pharmaceuticals, Inc.Promentis Pharmaceuticals, Inc.
01 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03301298 (CTgov)
Phase 1
-
48
(SXC-2023, 50 mg)
gliobhxuqv(xohxvsmwfe) = mrkbjkbwjg tfguxkrmzr (qvfhlccdnn, paeytpdysd - vmurecnrmk)
View more
-
26 Sep 2019
(SXC-2023, 100 mg)
gliobhxuqv(xohxvsmwfe) = wpmdisioth tfguxkrmzr (qvfhlccdnn, xxcpnpbzze - cxeqehifhq)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free